

ABSTRACT:

Provided are a monoclonal antibody specifically binding to BCMA, a BCMA and CD3 bispecific antibody, and a BCMA/GPRC5D/CD3 trispecific antibody constructed based on the BCMA monoclonal antibody. Further provided are a nucleic acid molecule encoding the antibodies, an expression vector for use in expressing the antibodies, a host cell, and a method. Further provided are an immunoconjugate, a bispecific molecule, a trispecific molecule, and a pharmaceutical composition comprising the antibodies, as well as a diagnostic and therapeutic method using the anti-BCMA antibody, the BCMA/CD3 bispecific antibody, and the BCMA/GPRC5D/CD3 trispecific antibody of the present disclosure.

[Figure 1]